Cellistic, the cell therapy development and manufacturing business of Ncardia BV, and Celyad Oncology, a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, announced a transaction whereby Cellistic will acquire Celyad Oncology’s Good Manufacturing Practice (GMP) grade cell therapy manufacturing capability, including the existing facility and all related personnel. Cellistic agreed to acquire Celyad On...